demonstrated that ginsenoside Rd effectively inhibited hyperphosphorylated tau (S199/202, S396, and S404) protein production and deposition by depressing GSK‐3β/Tyr216 expression, suggesting the potential therapeutic effect of ginsenoside Rd in early AD. The gene discussed is MAPT; the disease is Alzheimer disease.